Benign Prostatic Hyperplasia
Debruyne FMJ, Jardin A, Colloi D, et al [Univ Hosp. Nijmegen, The Netherlands; Hopital Bicetre, Kremlin- Bicetre, France; Ospedale Maggiore, Lodi, Italy; et al]
Sustained- Release Alfuzosin, Finasteride & the Combination of Both in the Treatment of Benign Prostatic Hyperplasia
Eur Urol 34: 169-175, 1998
Conclusions – Six months of therapy with sustained release alfuzosin either alone or in combination with finasteride, significantly improved LUTS in all patients, and significantly increased Qmax in those with low Qmax. Finasteride alone was not effective in treating LUTs and in addition to the a1 blocker provided no additional benefit.
R.S. Kirby, M. Andersen, P. Gratzke, C. Dahlstrand and K. Hoye [ St. George’s Hospital, London University, London, UK, Lillehammer County Hospital, Lillehammer, Norway, Rosenheim, Germany, Sahlgrenska University Hospital, Gotenburg, Sweden and General Practice, Elverum, Norway]
A Combined Analysis of Double-Blind Trials of the Efficacy and Tolerability of Doxazosin-Gastrointestinal Therapeutic System, Doxazosin Standard and Placebo in Patients with Benign Prostatic Hyperplasia
BJU International, volume 87, Number 1, January 2001, Pg.Nos. 192-200
Conclusion – Doxazosin GITS is significantly more effective than placebo in reducing the clinical symptoms of BPH and improving Qmax, and as effective as doxazosin-s. Both doxazosin formulations improved sexual function in patients with BPH and sexual dysfunction at baseline.
Doxazosin GITS produced a therapeutic effect equivalent to that of doxazocin-s but with fewer titration steps and a slightly lower overall incidence of adverse effects.
The GITS system has been developed to enhance the pharmacokinetic profile and drug delivery rate reducing the plasma doxazocin peak to trough ratio and minimizing the need for titration. The GITS formulation uses push-pull pump technology, allowing a more gradual controlled absorption of drug over a 24 hr period at steady state with once daily dosing. The alternations in the pharmocokinetic profile allow doxazosin GITS therapy to be initiated at a low dose.